Lpath, Inc. to Present at Association for Research in Vision & Ophthalmology Investor Seminar Focused on Unmet Clinical Needs

SAN DIEGO, CA--(Marketwire - April 28, 2011) - Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, is one of few companies invited to present at the April 29, 2011 seminar “Unmet Needs: Emerging Frontiers in Ophthalmic Science,” which was organized by the ARVO Foundation for Eye Research (AFER). ARVO (Association for Research in Vision and Ophthalmology) is the world’s largest organization of eye and vision scientists. This seminar precedes the ARVO Annual Meeting, which will be held in Ft. Lauderdale on May 1-5, 2011.

Lpath’s president and chief executive officer, Scott Pancoast, is scheduled to present on Friday, April 29 at 11:35 a.m. eastern time. He will focus on the potential of Lpath’s iSONEP™ drug candidate to provide differentiated patient benefits vis-à-vis drugs already approved for wet AMD and those in late-stage trials -- and thereby fulfill unmet clinical needs. He will also touch upon the company’s plans to further investigate iSONEP in two mid-stage trials, both of which are due to begin this quarter.

Lpath entered into an agreement with Pfizer in late 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP for any ocular indication. Pfizer and Lpath are collaborating closely on the two iSONEP clinical trials.

Other leading companies, as well as various distinguished researchers, will describe unmet needs and promising treatments for a variety of retinal disease and ocular-surface disorders at the seminar, which aims to help investors better understand the scientific and commercial environment of ophthalmic research.

Speakers include keynote presenter Anthony Adamis, M.D., of Genentech and Joan Miller, M.D., of Harvard Medical School.

One out of every 28 Americans over the age of 40 currently suffers from a serious, potentially blinding eye disease. Worldwide, an estimated 180 million people have been diagnosed with one or more of these diseases, a number that will increase dramatically as baby-boomer populations age and as emerging-nation health-care systems improve.

“Modern science and industry have made tremendous progress in preventing and treating eye disease,” explains lead organizer Nicholas Bazan, M.D., Ph.D., “but there is still a great need to develop more effective treatments and devices to help alleviate these conditions. Many areas of ophthalmic science require additional research support and these areas offer opportunities for commercial development.

“AFER’s Investors Seminar will provide a unique opportunity for private equity managers, venture capitalists, analysts and others to assess the value of emerging early and late stage treatments through an independent scientific and commercial lens. They will also join in discussion with the scientists and commercial experts who are working at the cutting edge of these fields.”

Complete program, venue and registration information is available at www.arvofoundation.org/investors.

About ARVO and AFER
The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include more than 12,500 eye and vision researchers from over 80 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology.

The ARVO Foundation for Eye Research (AFER) complements ARVO’s mission to further global eye and vision research by:

• Promoting scientific interactions and exchange
• Fostering translational research and moving forward scientific breakthroughs from the laboratory to clinical practice
• Recruiting and retaining scientists in all fields of vision research

About Lpath
San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath’s ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which -- iSONEP for wet AMD and ASONEP for cancer -- have completed Phase 1 clinical trials. Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.